Clinical Trials Logo

Healing Ulcer clinical trials

View clinical trials related to Healing Ulcer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05464407 Terminated - Healing Ulcer Clinical Trials

High Protein Oral Nutritional Support With Special Nutrients in Patients With Type 2 Diabetes and Foot Ulcer

Start date: February 24, 2022
Phase: N/A
Study type: Interventional

To assess the supplement of a high protein oral nutritional supplement enriched with arginin, zink, vitamin c and antioxidants on the healing of foot ulcers in patients with type 2 diabetes mellitus

NCT ID: NCT04963829 Completed - Chronic Ulcer Clinical Trials

Unripe Banana Peel Powder and Lemongrass Oil in Chronic Ulcer

Start date: February 2, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the activity of a gel composed of 10% peel powder of unripe banana (Musa sapientum) combined with lemongrass (Cymbopogon citratus) oil, at 0.1% concentration, in patients with chronic ulcers.

NCT ID: NCT03211910 Withdrawn - Healing Ulcer Clinical Trials

Sacral Savers: Study of Prevention and Enhanced Healing of Sacral and Trochenteric Ulcers

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the ability of the product "Sacral Saver," to prevent and /or help healing bed sores.

NCT ID: NCT01308177 Enrolling by invitation - Healing Ulcer Clinical Trials

Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection

Start date: March 2011
Phase: Phase 4
Study type: Interventional

- Endoscopic submucosal dissection (ESD) is widely indicated to treat gastric adenomas and early gastric cancer (EGC).ESD is able to obtain en bloc resection of larger specimens. However, ESD has more frequent complications (delayed bleeding, ulcer healing, ulcer pain, and etc) due to a more complex procedure. To prevent delayed bleeding, to induce rapid ulcer healing, and to control the ulcer pain acid-suppressing agents (PPI, H2RA) are generally administered. although PPIs are widely indicated as first-line drugs for peptic ulcers, PPI drugs are not fully superior to H2RAs or other combination drugs for treatment of iatrogenic ulcer healing and delayed bleeding. - Ecabet sodium (ES)is a widely used mucoprotective agent for the treatment of gastric ulcers. Recently, one study showed the additional benefits of using ES in combination with the PPI after ESD. however, this study did not show the difference of delayed bleeding and the benefit of ulcer pain control. thus, our study prospectively evaluated the difference of delayed bleeding and the benefit of ulcer pain control after ESD.